Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes
Open Access
- 30 April 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (1) , 302-305
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implicationsBlood, 2018
- High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factorsJournal of the Neurological Sciences, 2017
- Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM‐8 consensus panelBritish Journal of Haematology, 2017
- Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathiesCochrane Database of Systematic Reviews, 2016
- Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patientsHaematologica, 2013
- Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathyNeurology, 2013
- Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathyAnnals of Neurology, 2009
- Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and CyclophosphamideJournal of Clinical Oncology, 2007
- Frequency and clinical correlates of anti–neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathyAnnals of Neurology, 1994